CytoReason and Pfizer reach $110 million drug development deal
As part of a deal potentially worth $110 million over the next five years, CytoReason has announced an extension to its multi-year partnership with Pfizer.
Pfizer will make a capital investment of $20 million under the terms of the agreement which will give the company the right to use CytoReason’s artificial intelligence (AI) technology and the option to license its platform and disease models as well as fund additional project support.
Since launching the collaboration in 2019, Pfizer has used CytoReason’s biological models in its research to improve understanding of the immune system, while developing innovative drugs for immune-mediated and immuno-oncology diseases. CytoReason’s platform has provided Pfizer with extensive information on research and development programs for more than 20 diseases.
High resolution models
The new research agreement and investment will support the development of additional disease models and the creation of high-resolution models, covering a number of therapeutic areas.
“We are delighted to expand our strategic collaboration with CytoReason,” said Mikael Dolsten, Chief Scientific Officer and President of Pfizer. “We look forward to continuing our work with the company’s top scientists and leveraging its cutting-edge platform. CytoReason’s biodata enables us to better understand the best drug development pathways for patients, resulting in more informed, timely and cost-effective decisions.
CytoReason claims to have established itself as a global leader in computational modeling of human disease through its unique ability to combine computational models, proprietary human data, and the AI tools needed to deliver actionable insights to accelerate drug development .
About CytoReason’s multidisciplinary team
The company’s multidisciplinary team of 80 biologists, bioinformaticians and data engineers has developed a platform that enables pharmaceutical and biotechnology companies to prioritize new targets, find biomarkers and predict which patients might best respond to new treatments.
David Harel, CEO and Co-Founder of CytoReason, said, “Pfizer has been a strategic partner of CytoReason since 2019, and we are excited to extend our collaboration as one of Pfizer’s trusted AI partners for accelerate drug development.
“This partnership advances significant change in the biotech industry and helps guide future research and development for pharmaceutical companies as they continue to use machine learning to develop treatments more efficiently. Turning complex data into useful actionable insights will potentially provide leading researchers and scientists with a roadmap to further develop their drug portfolios.
CytoReason collects proprietary data from pharmaceutical companies and uses it to simulate human disease – tissue by tissue, cell by cell.